Trial results

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

NCT06326060 on ClinicalTrials.gov · last registry update 2026-04-15

An unusually large phase 2: 354 participants, more than double the 114 typical for the stage. The sponsor logged completion for 10 April 2025. Primary outcome, as filed: Relative change in body weight. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

354

Started

2024-03-18

Primary completion

2025-04-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Relative change in body weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.